Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

StemCells, Inc. to Present at Phacilitate Cell & Gene Therapy Forum



StemCells, Inc. to Present at Phacilitate Cell & Gene Therapy Forum

NEWARK, Calif., Jan. 23, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc.
(Nasdaq:STEM) announced today that Ann Tsukamoto, Ph.D., Executive Vice
President, Research and Development, will make a presentation on the Company's
clinical development programs at the Phacilitate Cell & Gene Therapy Forum to
be held January 28-30, in Washington, DC. Dr. Tsukamoto is scheduled to speak
at 12:25 p.m. ET on Wednesday, January 30, as part of the session on "Clinical
development updates from leading cell and gene therapy product candidates in
the clinic for CNS indications."

The Phacilitate Cell & Gene Therapy Forum is a preeminent industry-led meeting
designed to help advance regulatory, manufacturing, R&D and commercial
strategies and drive cell and gene therapy products forward. The Forum enables
executives from global cell therapy, gene therapy and tissue engineering
companies, representatives of big pharma and big biotech, regulators and
regulatory experts, and public and private investors to meet and share
information on the leading edge of the regenerative medicine sector.

About StemCells, Inc.

StemCells, Inc. is engaged in the research, development, and commercialization
of cell-based therapeutics and tools for use in stem cell-based research and
drug discovery. The Company's lead therapeutic product candidate, HuCNS-SC®
cells (purified human neural stem cells), is currently in development as a
potential treatment for a broad range of central nervous system disorders. In
a Phase I clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal
myelination disorder in children, the Company has shown preliminary evidence
of progressive and durable donor-derived myelination in all four patients
transplanted with HuCNS-SC cells. The Company is conducting a Phase I/II
clinical trial in chronic spinal cord injury in Switzerland and recently
reported positive interim data for the first patient cohort. The Company is
also conducting a Phase I/II clinical trial in dry age-related macular
degeneration (AMD), and is pursuing preclinical studies in Alzheimer's
disease. StemCells also markets stem cell research products, including media
and reagents, under the SC Proven® brand. Further information about StemCells
is available at http://www.stemcellsinc.com.

The StemCells, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=7014

Apart from statements of historical fact, the text of this press release
constitutes forward-looking statements within the meaning of the U.S.
securities laws, and is subject to the safe harbors created therein. These
statements include, but are not limited to, statements regarding the clinical
development of its HuCNS-SC cells; the Company's ability to commercialize drug
discovery and drug development tools; and the future business operations of
the Company. These forward-looking statements speak only as of the date of
this news release. The Company does not undertake to update any of these
forward-looking statements to reflect events or circumstances that occur after
the date hereof. Such statements reflect management's current views and are
based on certain assumptions that may or may not ultimately prove valid. The
Company's actual results may vary materially from those contemplated in such
forward-looking statements due to risks and uncertainties to which the Company
is subject, including those described under the heading "Risk Factors" in the
Company's Annual Report on Form 10-K for the year ended December 31, 2011 and
in its subsequent reports on Forms 10-Q and 8-K.

CONTACT: Rodney Young
         StemCells, Inc.
         Chief Financial Officer
         (510) 456-4128
        
         Ian Stone
         Russo Partners
         (619) 308-6541

company logo
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement